Aimei Health Technology Co., Ltd Announces Pricing of $60 Million Initial Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Source: businesswire
Updated: Dec 01 2023
0mins
Source: businesswire
Trade with 70% Backtested Accuracy
Stop guessing
"Should I Buy AFJKU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Sign upAnalyst Views on AFJKU
Wall Street analysts forecast AFJKU stock price to rise
Wall Street analysts forecast AFJKU stock price to rise
Current: 29.730

Current: 29.730


No data
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shareholder Notice: Legal Investigation Initiated for the Merger Involving AFJKU, CEPO, PBBK, and FNBT
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
Ongoing Investigations: The firm is investigating several companies, including Aimei Health Technology Co., Cantor Equity Partners, PB Bankshares, and FineMark Holdings, regarding their respective mergers and shareholder options, all of which are available for free consultation.
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Aimei Health Technology Co., Ltd (NASDAQ: AFJKU)
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, has been recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and is currently investigating Aimei Health Technology Co., Ltd's merger with United Hydrogen Global, Inc.
Shareholder Options: Aimei shareholders have the option to redeem their shares for $10.00 or become Class A shareholders in the merged company, which raises questions about the fairness of the deal.
Aimei Health Technology Co., Ltd. Announces the Separate Trading of its Ordinary Shares and Rights Commencing January 22, 2024
Aimei Health Technology Co., Ltd Announces Closing of $69 Million Initial Public Offering
Aimei Health Technology Co., Ltd Announces Pricing of $60 Million Initial Public Offering